Johnson & Johnson (JNJ) announced pivotal results from the Phase 1b/2 OrigAMI-4 study, which evaluated subcutaneous amivantamab with hyaluronidase-lpuj in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. The regimen delivered durable...
Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT) given for six months before and after prostate cancer surgery. The investigational regimen significantly improved both short-...
Pfizer Inc. (PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 BREAKWATER trial. This randomized cohort evaluated BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with...
Eli Lilly and Co. (LLY) announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) RET fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, showing a highly statistically...
MannKind Corp. (MNKD) announced that the U.S. Food and Drug Administration approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes. The approval expands Afrezza's availability beyond adults, introducing a new mealtime...
Oculis Holding AG (OCS) announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema (DME) did not achieve the primary endpoint. The mean change in best corrected visual acuity (BCVA) measured by ETDRS letter score at Week 52 was not met in either...
Pfizer Inc. (PFE) announced detailed results from the pivotal Phase 3 TALAPRO-3 study evaluating TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTANDI (enzalutamide), an androgen receptor pathway inhibitor, in men with homologous recombination repair (HRR) gene-mutated metastatic...
F.lli Ferrari Holding, ultimately owned by Mutares SE & Co. KGaA, has signed an agreement for the partial sale of its Netherlands distribution business to HMF Group. The transaction is expected to close in early June 2026, subject to customary closing conditions. The divested business generates approximately...
Lupin Limited announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g. The approved product is bioequivalent to the reference...
Rio Tinto announced that it has successfully started commissioning its $1.5 billion AP60 smelter expansion at Complexe Arvida in Quebec. This marks a significant milestone in deploying its state-of-the-art, low-carbon aluminium smelting technology. The start-up, which began in March, is expected to be...
Universal Music Group N.V. (UMG.AS, UNVGY, UMGNF), the Dutch-American music-based entertainment company, announced that its Board of Directors has unanimously determined that the unsolicited and non-binding proposal received from Pershing Square Capital Management, L.P. on April 7, 2026, is not in the...
Johnson & Johnson (JNJ) announced updated findings from the Phase 1/1b CHRYSALIS-2 study, which evaluated intravenous RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor...
Lundin Mining Corporation (LUN.TO) announced an update to its share capital and voting rights. As of May 29, 2026, the number of issued and outstanding shares decreased by 231,484, bringing the total to 855,378,907 common shares with voting rights. This reduction reflects share buybacks completed under...
Friday, Lanvin Group Holdings Limited (LANV) announced that its couture house in Paris, Maison Lanvin, has appointed Barbara Werschine as Chief Executive Officer. Most recently, Werschine served as CEO of Eric Bompard, where she successfully modernized the brand and optimized its financial performance. Upon...
Dizal (688192.SS) announced the results from the phase 3 WU-KONG28 study showing that ZEGFROVY monotherapy demonstrated superior anti-tumor efficacy, compared to platinum-doublet chemotherapy, in untreated NSCLC patients with EGFR exon 20 insertion mutations. Xiaolin Zhang, CEO of Dizal, said: "WU-KONG28...
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.